Dalbavancin as long-term infection control: a safety study
Part of Infections clinical trials.
This study looks back at patients who received the antibiotic dalbavancin as a long-term suppressive therapy for stubborn infections. It aims to see how well it worked and if it was safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You received the antibiotic dalbavancin as a long-term infection-fighting treatment (suppressive therapy) between July 2019 and December 2024.
- You have been told about this study and have no objection to joining.
- You had a chronic or long-lasting infection that didn't clear up with previous treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a better way to give a long-acting antibiotic called dalbavancin for serious bacterial infections. Dalbavancin is given as an infusion and may allow you to leave the hospital sooner while still completing your antibiotic treatment.
This trial tests whether dalbavancin (an antibiotic given as a dose or doses) works as well as standard antibiotics to treat bloodstream infections related to a removed IV catheter caused by Staphylococcus aureus. It may help reduce treatment time and dosing complexity if you qualify.
This study tests a new antibiotic called dalbavancin for treating infections of the heart valves. It may offer a simpler treatment option with fewer hospital visits.
This trial tests whether an antibiotic called dalbavancin, given to prevent bacterial infections during chemotherapy-induced low white blood cell counts, is safe and works in children and young adults with certain types of leukemia. It may help reduce the risk of serious infections during treatment.
This study checks how safe sulbactam-durlobactam (a combination antibiotic) is in adults with a serious infection caused by ABC bacteria, especially looking for allergic reactions. If you are already getting this antibiotic as part of your care, you may be able to join.
This trial tests an investigational antibiotic called BAL2420 to see if it is safe and how the body processes it. Healthy volunteers are needed to help determine the right dose before it can be studied in people with infections.
Hear when a new Efficacy and Safety of Dalbavancin trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.